A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Latest Information Update: 03 Jul 2025
At a glance
- Drugs DCSZ 11 (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors DynamiCure Biotechnology
Most Recent Events
- 26 Jun 2025 Addition of 1 treatment arm ,patient number has been increased ,patient inclusion criteria have been changed
- 26 Jun 2025 Planned number of patients changed from 257 to 320.
- 26 Jun 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.